Assisted Reproductive Technology Market - Global Forecast to 2030
商品番号 : SMB-75803
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年3月 |
| ページ数 | 321 |
| 図表数 | 374 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The assisted reproductive technology market is projected to reach USD 6.02 Billion by 2030 from USD 4.29 Billion in 2025 at a CAGR of 7.0% during the forecast period.
生殖補助医療（ART）市場は、予測期間中に年平均成長率 7.0% で成長し、2025 年の 42 億 9,000 万米ドルから 2030 年までに 60 億 2,000 万米ドルに達すると予測されています。
Increasing rates of infertility due to delayed conception, altered lifestyles, and growing awareness of fertility treatment are driving the assisted reproductive technology (ART) market. Further impetus to market growth is coming from improvements in medical technology, improved treatment success rates with in-vitro fertilization (IVF), and favorable government policies. But some of these limitations are the cost of treatment, ethical and legal issues, and health risks associated with ART procedures. Inadequacy of fertility treatment in developing nations and physical and psychological stress of ART also limit market growth. Research and development are, in spite of these limitations, enhancing the price and effectiveness of ART treatments.
受胎の遅れ、ライフスタイルの変化、不妊治療に対する意識の高まりによる不妊率の上昇が、生殖補助医療 (ART) 市場の牽引役となっています。医療技術の向上、体外受精 (IVF) による治療成功率の向上、政府の好ましい政策も、市場の成長を後押ししています。しかし、治療費、倫理的および法的問題、ART 処置に伴う健康リスクなど、こうした制約もあります。発展途上国における不妊治療の不十分さや、ART による身体的および精神的ストレスも、市場の成長を制限しています。こうした制約にもかかわらず、研究開発により、ART 治療の価格と効果は向上しています。
“The IVF segment is accounted for the largest share of global assisted reproductive technology market.”
IVF has become the ART procedure of choice over other treatments due to innovations like time-lapse imaging, embryo freezing, and preimplantation genetic testing (PGT), which have greatly enhanced IVF success. Global demand for IVF has also been driven by delayed pregnancy, rising infertility, and greater awareness of fertility treatment. IVF domination of the market is also driven by greater medical tourism practice, government subsidization of ART procedures, and greater numbers of fertility clinics.
Due to its high success rates, commonality of use, and ongoing technological advancements, the IVF category maintains the largest market share in the assisted reproductive technology (ART) market.
The best treatment for infertility, in vitro fertilization (IVF), can treat many different kinds of infertility problems, including unexplained infertility, male factor infertility, and older mother age.
“Fertility clinics has the largest market share in assisted reproductive technology market.”
Fertility clinics enjoy the largest market share among the assisted reproductive technology market in care facilities owing to the growing demand for specialist reproductive treatments, high-technology healthcare facilities, and the increased number of infertile patients worldwide. Since ART therapies provided are heterogeneous in nature, encompassing intrauterine insemination, in-vitro fertilization, freezing eggs and sperm, and preimplantation genetic diagnosis, fertility clinics remain the preferred option for those who require fertility therapies. Expansion of private fertility clinics, government initiatives, and growing awareness regarding reproductive therapies have also driven the growth of this segment. Fertility clinics’ dominance in the ART business is also complemented by the growing trend of medical tourism for affordable ART therapy in Thailand, India, and Spain.
“Asia Pacific holds the largest market share in the assisted reproductive technology market.”
Asia-Pacific holds the maximum market share in the ART market due to its large population, large infertility rates, and strong awareness of fertility treatment. There is growing demand for ART treatment in the region at a rapid rate due to factors such as delayed parenthood, changing lifestyles, and high levels of stress that exacerbate fertility. Government-sponsored programs for ART funding, the proliferation of fertility clinics, and advances in reproductive technology have all contributed to the growth in the market. Key drivers are countries such as China, India, and Japan, which offer low-cost fertility treatments that are in great demand among medical tourists. Asia-Pacific’s market dominance is also supported by increasing acceptance of ART as well as the increase in the affordability of healthcare and infrastructure.
A breakdown of the primary participants (supply-side) for the assisted reproductive technology market referred to for this report is provided below:
- By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3–30%
- By Designation: C-level–55%, Director Level–27%, and Others–18%
- By Region: North America–35%, Europe–32%, Asia Pacific–25%, Latin America- 5%, and Middle East and Africa– 1% and GCC Countries– 2%
Prominent players in this market include CooperSurgical Inc. (US), FUJIFILM Irvine Scientific (Japan), Vitrolife (Sweden), Hamilton Thorne (US), Cook Medical Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea BIOMEDX (Australia), Thermo Fisher Scientific Inc. (US), LENUS Pharma GesmbH (Austria), Zita West (UK), Kitazato Corporation (Japan), Exeltis USA, Inc. (US), Vitabiotics Ltd (UK), FertiPro NV (Belgium), and AdvaCare Pharma (US), among others.
Research Coverage:
The market study covers the assisted reproductive technology market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by type, technology, patient type, care setting and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
- Analysis of Market Dynamics: Drivers (Increasing median age of pregnancy, Rising infertility rate, Booming fertility industry, Evolving technological landscape, Favorable government initiatives) restraints (High cost of IVF procedures, Social and ethical concerns in developing countries, Elevated risk of complications) opportunities (Growth opportunities in emerging economies, Availability of diverse range of fertility treatment options), and challenges (Reduced efficacy of infertility treatments among patients of advanced age)
- Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new product launches in the assisted reproductive technology market.
- Market Development: Comprehensive information on the lucrative emerging markets, components, demographics, care settings, and region.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the assisted reproductive technology market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the assisted reproductive technology market like CooperSurgical Inc. (US), FUJIFILM Irvine Scientific (Japan), Vitrolife (Sweden), Hamilton Thorne (US), Cook Medical Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea BIOMEDX (Australia), and Thermo Fisher Scientific Inc. (US).
Table of Contents
1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 30
1.3 STUDY SCOPE 30
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 30
1.3.2 INCLUSIONS AND EXCLUSIONS 31
1.3.3 YEARS CONSIDERED 32
1.4 CURRENCY CONSIDERED 32
1.5 STAKEHOLDERS 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.2 RESEARCH DESIGN 34
2.2.1 SECONDARY RESEARCH 35
2.2.1.1 Key data from secondary sources 36
2.2.2 PRIMARY RESEARCH 37
2.2.2.1 Primary sources 37
2.2.2.2 Key industry insights 38
2.2.2.3 Breakdown of primary interviews 38
2.3 MARKET SIZE ESTIMATION 39
2.3.1 SUPPLY-SIDE ANALYSIS 40
2.3.2 BOTTOM-UP APPROACH 42
2.3.2.1 Company revenue estimation approach 42
2.3.2.2 Customer-based market estimation 43
2.3.2.3 Demand-side market size estimation 43
2.3.2.4 Growth forecast approach 44
2.4 DATA TRIANGULATION 47
2.5 MARKET SHARE ASSESSMENT 48
2.6 RESEARCH ASSUMPTIONS 48
2.7 RESEARCH LIMITATIONS 48
2.8 RISK ASSESSMENT 49
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 55
4.1 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET OVERVIEW 55
4.2 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY TYPE AND COUNTRY 56
4.3 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET:
GEOGRAPHIC GROWTH OPPORTUNITIES 57
4.4 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: REGIONAL MIX 58
4.5 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET:
DEVELOPED VS. DEVELOPING MARKETS 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 61
5.2.1 DRIVERS 62
5.2.1.1 Increasing median age of pregnancy 62
5.2.1.2 Rising infertility rate 63
5.2.1.3 Booming fertility industry 64
5.2.1.4 Evolving technological landscape 65
5.2.1.5 Favorable government initiatives 67
5.2.2 RESTRAINTS 68
5.2.2.1 High cost of IVF procedures 68
5.2.2.2 Social and ethical concerns in developing countries 68
5.2.2.3 Elevated risk of complications 69
5.2.3 OPPORTUNITIES 70
5.2.3.1 Growth opportunities in emerging economies 70
5.2.3.2 Availability of diverse range of fertility treatment options 70
5.2.4 CHALLENGES 70
5.2.4.1 Reduced efficacy of infertility treatments for patients of
advanced age 70
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 71
5.4 PRICING ANALYSIS 72
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS 72
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION 73
5.5 VALUE CHAIN ANALYSIS 73
5.5.1 RESEARCH & PRODUCT DEVELOPMENT 75
5.5.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING 75
5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 75
5.6 SUPPLY CHAIN ANALYSIS 75
5.6.1 PROMINENT COMPANIES 75
5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES 75
5.6.3 END USERS 75
5.7 ECOSYSTEM ANALYSIS 76
5.8 INVESTMENT AND FUNDING SCENARIO 77
5.9 TECHNOLOGY ANALYSIS 78
5.9.1 KEY TECHNOLOGIES 78
5.9.1.1 Time-lapse technology 78
5.9.2 COMPLEMENTARY TECHNOLOGIES 79
5.9.2.1 Preimplantation genetic testing 79
5.9.3 ADJACENT TECHNOLOGIES 79
5.9.3.1 Sperm cryopreservation 79
5.9.3.2 Oocyte cryopreservation 80
5.10 PATENT ANALYSIS 81
5.11 TRADE DATA ANALYSIS 83
5.11.1 IMPORT DATA 83
5.11.2 EXPORT DATA 84
5.12 KEY CONFERENCES AND EVENTS, 2025–2026 85
5.13 CASE STUDY ANALYSIS 86
5.13.1 CASE STUDY 1: ENHANCED IVF RATES USING EMBRYOTOXICITY, PLATELET LEUKOCYTE AGGREGATES, AND NATURAL KILLER DIAGNOSIS 86
5.13.2 CASE STUDY 2: IMPROVED EMBRYO SELECTION
THROUGH AI-DRIVEN PLATFORM 86
5.13.3 CASE STUDY 3: ASSESSMENT OF EMBRYO VIABILITY
USING AI-DRIVEN SYSTEMS 87
5.14 REGULATORY LANDSCAPE 87
5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
5.14.2 REGULATORY FRAMEWORK 90
5.14.2.1 North America 91
5.14.2.1.1 US 91
5.14.2.1.2 Canada 91
5.14.2.2 Europe 92
5.14.2.3 Asia Pacific 92
5.14.2.3.1 India 92
5.14.2.3.2 Japan 92
5.15 PORTER’S FIVE FORCES ANALYSIS 93
5.15.1 THREAT OF NEW ENTRANTS 94
5.15.2 THREAT OF SUBSTITUTES 94
5.15.3 BARGAINING POWER OF BUYERS 94
5.15.4 BARGAINING POWER OF SUPPLIERS 94
5.15.5 INTENSITY OF COMPETITIVE RIVALRY 94
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 95
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 95
5.16.2 BUYING CRITERIA 96
5.17 UNMET NEEDS 97
5.18 REIMBURSEMENT SCENARIO 97
5.19 IMPACT OF AI/GEN AI ON ASSISTED REPRODUCTIVE TECHNOLOGY MARKET 98
5.19.1 INTRODUCTION 98
5.19.2 MARKET POTENTIAL OF AI IN ASSISTED REPRODUCTIVE TECHNOLOGY 98
5.19.3 AI USE CASES 99
5.19.4 KEY COMPANIES IMPLEMENTING AI 100
5.19.5 FUTURE OF GENERATIVE AI IN ASSISTED REPRODUCTIVE
TECHNOLOGY MARKET 100
6 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE 101
6.1 INTRODUCTION 102
6.2 IN VITRO FERTILIZATION 102
6.2.1 IVF WITH ICSI 103
6.2.1.1 Higher success rates than conventional methods to stimulate growth 103
6.2.2 IVF WITHOUT ICSI 104
6.2.2.1 Preferred choice for less severe infertility issues to facilitate growth 104
6.3 ARTIFICIAL INSEMINATION 105
6.3.1 GROWING PREFERENCE FOR MINIMALLY INVASIVE TREATMENTS
TO DRIVE MARKET 105
7 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE 107
7.1 INTRODUCTION 108
7.2 INSTRUMENTS 108
7.2.1 EMBRYO INCUBATORS 109
7.2.1.1 Need for undisturbed and protective environment throughout incubation to aid growth 109
7.2.2 SPERM ANALYZER SYSTEMS 111
7.2.2.1 Capability to identify fertility problems and determine appropriate interventions to fuel market 111
7.2.3 MICROMANIPULATORS 113
7.2.3.1 Increased adoption of micromanipulators in intracytoplasmic sperm injections and embryo biopsies to boost market 113
7.2.4 OTHER INSTRUMENTS 115
7.3 MEDIA 116
7.3.1 EMBRYO CULTURE MEDIA 118
7.3.1.1 Close resemblance to natural environment to amplify growth 118
7.3.2 CRYOPRESERVATION MEDIA 119
7.3.2.1 Ability to protect cells from damage to drive market 119
7.3.3 SEMEN PROCESSING MEDIA 120
7.3.3.1 Growing application in washing, capacitation, and sperm selection to boost market 120
7.3.4 OVUM PROCESSING MEDIA 121
7.3.4.1 Ability to mimic natural conditions of female reproductive tract
to aid growth 121
7.4 SUPPLEMENTS 122
7.4.1 RISING DEMAND FOR FERTILITY-ENHANCING SUPPLEMENTS TO SUPPORT GROWTH 122
7.5 CONSUMABLES 123
7.5.1 CULTURE DISHES & PLATES 124
7.5.1.1 Growing advancements in embryo incubation to drive market 124
7.5.2 STORAGE CONTAINERS 125
7.5.2.1 Increasing use of cryopreservation techniques to expedite growth 125
7.5.3 CRYOVIALS & TUBES 127
7.5.3.1 Growing trend of egg and embryo freezing for delayed parenthood to boost market 127
7.5.4 OTHER CONSUMABLES 128
8 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE 129
8.1 INTRODUCTION 130
8.2 FEMALE PATIENTS 130
8.2.1 RISING FEMALE INFERTILITY RATE TO AMPLIFY GROWTH 130
8.3 MALE PATIENTS 131
8.3.1 LIFESTYLE CHANGES AND INCREASING INCIDENCE OF LOW SPERM COUNT TO PROMOTE GROWTH 131
9 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER 133
9.1 INTRODUCTION 134
9.2 FERTILITY CLINICS 134
9.2.1 INCREASED AVAILABILITY AND ACCESSIBILITY OF FERTILITY
CLINICS TO SUSTAIN GROWTH 134
9.3 HOSPITALS & SURGERY CLINICS 135
9.3.1 NEED FOR ADVANCED LABORATORIES FOR GAMETE HANDLING AND ULTRASOUND MONITORING TO AID GROWTH 135
9.4 RESEARCH INSTITUTES 137
9.4.1 ONGOING RESEARCH FOR COST-EFFECTIVE AND ADVANCED
TECHNIQUES TO STIMULATE GROWTH 137
9.5 CRYOBANKS 138
9.5.1 GROWING INCLINATION TOWARD FLEXIBLE TREATMENT TO FUEL MARKET 138
10 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION 140
10.1 INTRODUCTION 141
10.2 NORTH AMERICA 142
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 142
10.2.2 US 147
10.2.2.1 Favorable infrastructure network to encourage growth 147
10.2.3 CANADA 151
10.2.3.1 Growing assistance from banks for fertility treatments to fuel market 151
10.3 EUROPE 156
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 157
10.3.2 GERMANY 162
10.3.2.1 Robust healthcare infrastructure to support growth 162
10.3.3 UK 166
10.3.3.1 Increasing focus on high-quality care at licensed fertility
clinics to propel market 166
10.3.4 FRANCE 170
10.3.4.1 Growing healthcare expenditure to boost market 170
10.3.5 ITALY 174
10.3.5.1 Favorable regulatory guidelines to support market growth 174
10.3.6 SPAIN 178
10.3.6.1 Booming medical tourism to drive market 178
10.3.7 REST OF EUROPE 182
10.4 ASIA PACIFIC 186
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 187
10.4.2 CHINA 193
10.4.2.1 Increasing medical benefits for childbirth to intensify growth 193
10.4.3 JAPAN 197
10.4.3.1 Low fertility rates to amplify growth 197
10.4.4 INDIA 201
10.4.4.1 Affordable treatment options to favor growth 201
10.4.5 AUSTRALIA 205
10.4.5.1 Declining fertility rate to advance growth 205
10.4.6 SOUTH KOREA 209
10.4.6.1 Growing focus on reversing low population trend to drive market 209
10.4.7 REST OF ASIA PACIFIC 213
10.5 LATIN AMERICA 217
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 217
10.5.2 BRAZIL 222
10.5.2.1 Rise in aging mothers to contribute to growth 222
10.5.3 MEXICO 226
10.5.3.1 Growing network of state-of-the-art facilities to boost market 226
10.5.4 REST OF LATIN AMERICA 230
10.6 MIDDLE EAST & AFRICA 234
10.6.1 RISING HEALTHCARE SPENDING TO FOSTER GROWTH 234
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 235
10.7 GCC COUNTRIES 239
10.7.1 IMPROVED HEALTH INFRASTRUCTURE AND BETTER AWARENESS ABOUT FERTILITY TREATMENTS TO PROPEL MARKET 239
10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 240
11 COMPETITIVE LANDSCAPE 245
11.1 OVERVIEW 245
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 245
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET 246
11.3 REVENUE ANALYSIS, 2020–2024 247
11.4 MARKET SHARE ANALYSIS, 2024 248
11.5 COMPANY VALUATION AND FINANCIAL METRICS 250
11.5.1 COMPANY VALUATION 250
11.5.2 FINANCIAL METRICS 250
11.6 BRAND/PRODUCT COMPARISON 251
11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 252
11.7.1 STARS 252
11.7.2 EMERGING LEADERS 252
11.7.3 PERVASIVE PLAYERS 252
11.7.4 PARTICIPANTS 252
11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 254
11.7.5.1 Company footprint 254
11.7.5.2 Region footprint 255
11.7.5.3 Type footprint 256
11.7.5.4 Product type footprint 257
11.7.5.5 Patient type footprint 258
11.7.5.6 End-user footprint 259
11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 260
11.8.1 PROGRESSIVE COMPANIES 260
11.8.2 RESPONSIVE COMPANIES 260
11.8.3 DYNAMIC COMPANIES 260
11.8.4 STARTING BLOCKS 260
11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 262
11.8.5.1 Detailed list of key startups/SMEs 262
11.8.5.2 Competitive benchmarking of key startups/SMEs 263
11.9 COMPETITIVE SCENARIO 263
11.9.1 PRODUCT LAUNCHES 263
11.9.2 DEALS 264
11.9.3 OTHER DEVELOPMENTS 265
12 COMPANY PROFILES 266
12.1 KEY PLAYERS 266
12.1.1 COOPERSURGICAL INC. 266
12.1.1.1 Business overview 266
12.1.1.2 Products offered 267
12.1.1.3 Recent developments 269
12.1.1.3.1 Deals 269
12.1.1.4 MnM view 269
12.1.1.4.1 Key strengths 269
12.1.1.4.2 Strategic choices 269
12.1.1.4.3 Weaknesses and competitive threats 269
12.1.2 FUJIFILM IRVINE SCIENTIFIC 270
12.1.2.1 Business overview 270
12.1.2.2 Products offered 271
12.1.2.3 Recent developments 271
12.1.2.3.1 Deals 271
12.1.2.3.2 Other developments 272
12.1.2.4 MnM view 272
12.1.2.4.1 Key strengths 272
12.1.2.4.2 Strategic choices 272
12.1.2.4.3 Weaknesses 272
12.1.3 VITROLIFE 273
12.1.3.1 Business overview 273
12.1.3.2 Products offered 275
12.1.3.3 Recent developments 275
12.1.3.3.1 Deals 275
12.1.3.4 MnM view 276
12.1.3.4.1 Key strengths 276
12.1.3.4.2 Strategic choices 276
12.1.3.4.3 Weaknesses and competitive threats 276
12.1.4 THERMO FISHER SCIENTIFIC INC. 277
12.1.4.1 Business overview 277
12.1.4.2 Products offered 278
12.1.4.3 MnM view 279
12.1.4.3.1 Key strengths 279
12.1.4.3.2 Strategic choices 279
12.1.4.3.3 Weaknesses and competitive threats 279
12.1.5 COOK MEDICAL INC. 280
12.1.5.1 Business overview 280
12.1.5.2 Products offered 280
12.1.5.3 Recent developments 281
12.1.5.3.1 Product launches 281
12.1.5.3.2 Deals 282
12.1.5.4 MnM view 282
12.1.5.4.1 Key strengths 282
12.1.5.4.2 Strategic choices 282
12.1.5.4.3 Weaknesses and competitive threats 282
12.1.6 HAMILTON THORNE 283
12.1.6.1 Business overview 283
12.1.6.2 Products offered 283
12.1.6.3 Recent developments 284
12.1.6.3.1 Deals 284
12.1.6.4 MnM view 285
12.1.6.4.1 Key strengths 285
12.1.6.4.2 Strategic choices 285
12.1.6.4.3 Weaknesses and competitive threats 285
12.1.7 KITAZATO CORPORATION 286
12.1.7.1 Business overview 286
12.1.7.2 Products offered 286
12.1.7.3 Recent developments 288
12.1.7.3.1 Deals 288
12.1.8 ESCO MICRO PTE. LTD. 289
12.1.8.1 Business overview 289
12.1.8.2 Products offered 289
12.1.8.3 Recent developments 290
12.1.8.3.1 Deals 290
12.1.9 FERTIPRO NV 291
12.1.9.1 Business overview 291
12.1.9.2 Products offered 291
12.1.10 GENEA BIOMEDX 293
12.1.10.1 Business overview 293
12.1.10.2 Products offered 293
12.1.10.3 Recent developments 294
12.1.10.3.1 Deals 294
12.1.11 LENUS PHARMA GESMBH 295
12.1.11.1 Business overview 295
12.1.11.2 Products offered 295
12.1.11.3 Recent developments 295
12.1.11.3.1 Product launches 295
12.1.12 ZITA WEST 296
12.1.12.1 Business overview 296
12.1.12.2 Products offered 296
12.1.13 EXELTIS USA, INC. 298
12.1.13.1 Business overview 298
12.1.13.2 Products offered 298
12.1.14 VITABIOTICS LTD. 299
12.1.14.1 Business overview 299
12.1.14.2 Products offered 299
12.1.15 ADVACARE PHARMA 301
12.1.15.1 Business overview 301
12.1.15.2 Products offered 301
12.2 OTHER COMPANIES 302
12.2.1 FAIRHAVEN HEALTH 302
12.2.2 SHANGHAI UNICORN MEDICAL TECHNOLOGY CO., LTD. 303
12.2.3 GYNEMED GMBH & CO. KG 304
12.2.4 INVITROCARE INC. 305
12.2.5 IVFTECH 306
12.2.6 LABIVF ASIA PTE LTD. 307
12.2.7 COAST SCIENCE 308
12.2.8 BIOIMAGER INC. 309
12.2.9 SHIVANI SCIENTIFIC 310
12.2.10 MINITÜB GMBH 311
13 APPENDIX 312
13.1 DISCUSSION GUIDE 312
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 317
13.3 CUSTOMIZATION OPTIONS 319
13.4 RELATED REPORTS 319
13.5 AUTHOR DETAILS 320
LIST OF TABLES
TABLE 1 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: INCLUSIONS AND EXCLUSIONS 31
TABLE 2 STANDARD CURRENCY CONVERSION RATES, 2019–2023 32
TABLE 3 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT TYPE,
2022–2024 (USD) 72
TABLE 4 AVERAGE SELLING PRICE TREND OF SUPPLEMENTS, BY REGION,
2022–2024 (USD) 73
TABLE 5 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET:
ROLE OF COMPANIES IN ECOSYSTEM 77
TABLE 6 INNOVATIONS AND PATENT REGISTRATIONS, 2022–2024 82
TABLE 7 IMPORT DATA FOR HS CODE 901890, BY COUNTRY,
2020–2024 (USD THOUSAND) 83
TABLE 8 EXPORT DATA FOR HS CODE 901890, BY COUNTRY,
2020–2024 (USD THOUSAND) 84
TABLE 9 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: KEY CONFERENCES
AND EVENTS, 2025–2026 85
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 87
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 88
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 89
TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 89
TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 90
TABLE 15 REGULATORY STANDARDS AND APPROVALS FOR ASSISTED REPRODUCTIVE TECHNOLOGY 90
TABLE 16 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 93
TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR
TOP TWO END USERS (%) 95
TABLE 18 KEY BUYING CRITERIA FOR TOP TWO END USERS 96
TABLE 19 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: CURRENT UNMET NEEDS 97
TABLE 20 MAJOR CPT CODES FOR LASER PROCEDURES IN US, 2024 97
TABLE 21 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 102
TABLE 22 ASSISTED REPRODUCTIVE TYPE MARKET FOR IVF, BY TYPE,
2022–2030 (USD MILLION) 102
TABLE 23 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY COUNTRY,
2022–2030 (USD MILLION) 103
TABLE 24 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF WITH ICSI,
BY COUNTRY, 2022–2030 (USD MILLION) 104
TABLE 25 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF WITHOUT ICSI,
BY COUNTRY, 2022–2030 (USD MILLION) 105
TABLE 26 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR ARTIFICIAL INSEMINATION, BY COUNTRY, 2022–2030 (USD MILLION) 106
TABLE 27 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE,
2022–2030 (USD MILLION) 108
TABLE 28 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS,
BY TYPE, 2022–2030 (USD MILLION) 108
TABLE 29 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS,
BY COUNTRY, 2022–2030 (USD MILLION) 109
TABLE 30 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR EMBRYO INCUBATORS,
BY COUNTRY, 2022–2030 (USD MILLION) 110
TABLE 31 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR EMBRYO INCUBATORS,
BY REGION, 2022–2030 (THOUSAND UNITS) 111
TABLE 32 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR SPERM ANALYZER SYSTEMS, BY COUNTRY, 2022–2030 (USD MILLION) 112
TABLE 33 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR SPERM ANALYZER SYSTEMS, BY REGION, 2022–2030 (THOUSAND UNITS) 113
TABLE 34 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MICROMANIPULATORS,
BY COUNTRY, 2022–2030 (USD MILLION) 114
TABLE 35 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MICROMANIPULATORS,
BY REGION, 2022–2030 (THOUSAND UNITS) 115
TABLE 36 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR OTHER INSTRUMENTS,
BY COUNTRY, 2022–2030 (USD MILLION) 116
TABLE 37 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE,
2022–2030 (USD MILLION) 117
TABLE 38 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY COUNTRY, 2022–2030 (USD MILLION) 117
TABLE 39 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR EMBRYO CULTURE MEDIA, BY COUNTRY, 2022–2030 (USD MILLION) 118
TABLE 40 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CRYOPRESERVATION MEDIA, BY COUNTRY, 2022–2030 (USD MILLION) 119
TABLE 41 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR SEMEN PROCESSING MEDIA, BY COUNTRY, 2022–2030 (USD MILLION) 120
TABLE 42 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR OVUM PROCESSING MEDIA, BY COUNTRY, 2022–2030 (USD MILLION) 121
TABLE 43 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR SUPPLEMENTS,
BY COUNTRY, 2022–2030 (USD MILLION) 122
TABLE 44 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 123
TABLE 45 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES,
BY COUNTRY, 2022–2030 (USD MILLION) 124
TABLE 46 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CULTURE DISHES & PLATES, BY COUNTRY, 2022–2030 (USD MILLION) 125
TABLE 47 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR STORAGE CONTAINERS,
BY COUNTRY, 2022–2030 (USD MILLION) 126
TABLE 48 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CRYOVIALS & TUBES,
BY COUNTRY, 2022–2030 (USD MILLION) 127
TABLE 49 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR OTHER CONSUMABLES,
BY COUNTRY, 2022–2030 (USD MILLION) 128
TABLE 50 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE,
2022–2030 (USD MILLION) 130
TABLE 51 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR FEMALE PATIENTS,
BY COUNTRY, 2022–2030 (USD MILLION) 131
TABLE 52 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MALE PATIENTS,
BY COUNTRY, 2022–2030 (USD MILLION) 132
TABLE 53 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2022–2030 (USD MILLION) 134
TABLE 54 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR FERTILITY CLINICS,
BY COUNTRY, 2022–2030 (USD MILLION) 135
TABLE 55 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR HOSPITALS & SURGERY CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 136
TABLE 56 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR RESEARCH INSTITUTES,
BY COUNTRY, 2022–2030 (USD MILLION) 138
TABLE 57 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CRYOBANKS, BY COUNTRY, 2022–2030 (USD MILLION) 139
TABLE 58 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION,
2022–2030 (USD MILLION) 141
TABLE 59 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 144
TABLE 60 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 144
TABLE 61 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF,
BY TYPE, 2022–2030 (USD MILLION) 144
TABLE 62 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 145
TABLE 63 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 145
TABLE 64 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 146
TABLE 65 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 146
TABLE 66 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY PATIENT TYPE, 2022–2030 (USD MILLION) 147
TABLE 67 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY END USER, 2022–2030 (USD MILLION) 147
TABLE 68 US: KEY MACROECONOMIC INDICATORS 148
TABLE 69 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 148
TABLE 70 US: IVF ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, FOR IVF,
BY TYPE, 2022–2030 (USD MILLION) 148
TABLE 71 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE,
2022–2030 (USD MILLION) 149
TABLE 72 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS,
BY TYPE, 2022–2030 (USD MILLION) 149
TABLE 73 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 150
TABLE 74 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 150
TABLE 75 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE,
2022–2030 (USD MILLION) 151
TABLE 76 US: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2022–2030 (USD MILLION) 151
TABLE 77 CANADA: KEY MACROECONOMIC INDICATORS 152
TABLE 78 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 153
TABLE 79 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 153
TABLE 80 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 154
TABLE 81 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 154
TABLE 82 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA,
BY TYPE, 2022–2030 (USD MILLION) 155
TABLE 83 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 155
TABLE 84 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 156
TABLE 85 CANADA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2022–2030 (USD MILLION) 156
TABLE 86 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 158
TABLE 87 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 158
TABLE 88 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 159
TABLE 89 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 159
TABLE 90 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 160
TABLE 91 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 160
TABLE 92 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 161
TABLE 93 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 161
TABLE 94 EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2022–2030 (USD MILLION) 162
TABLE 95 GERMANY: KEY MACROECONOMIC INDICATORS 162
TABLE 96 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 163
TABLE 97 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 163
TABLE 98 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 163
TABLE 99 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 164
TABLE 100 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA,
BY TYPE, 2022–2030 (USD MILLION) 164
TABLE 101 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 165
TABLE 102 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 165
TABLE 103 GERMANY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 166
TABLE 104 UK: KEY MACROECONOMIC INDICATORS 166
TABLE 105 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 167
TABLE 106 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE,
2022–2030 (USD MILLION) 167
TABLE 107 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE,
2022–2030 (USD MILLION) 168
TABLE 108 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS,
BY TYPE, 2022–2030 (USD MILLION) 168
TABLE 109 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 169
TABLE 110 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 169
TABLE 111 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE,
2022–2030 (USD MILLION) 170
TABLE 112 UK: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2022–2030 (USD MILLION) 170
TABLE 113 FRANCE: KEY MACROECONOMIC INDICATORS 171
TABLE 114 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 171
TABLE 115 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 171
TABLE 116 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 172
TABLE 117 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS,
BY TYPE, 2022–2030 (USD MILLION) 172
TABLE 118 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA,
BY TYPE, 2022–2030 (USD MILLION) 173
TABLE 119 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 173
TABLE 120 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 174
TABLE 121 FRANCE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2022–2030 (USD MILLION) 174
TABLE 122 ITALY: KEY MACROECONOMIC INDICATORS 175
TABLE 123 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 175
TABLE 124 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE,
2022–2030 (USD MILLION) 175
TABLE 125 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 176
TABLE 126 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS,
BY TYPE, 2022–2030 (USD MILLION) 176
TABLE 127 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 177
TABLE 128 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 177
TABLE 129 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE,
2022–2030 (USD MILLION) 178
TABLE 130 ITALY: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2022–2030 (USD MILLION) 178
TABLE 131 SPAIN: KEY MACROECONOMIC INDICATORS 179
TABLE 132 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 179
TABLE 133 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE,
2022–2030 (USD MILLION) 179
TABLE 134 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 180
TABLE 135 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS,
BY TYPE, 2022–2030 (USD MILLION) 180
TABLE 136 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 181
TABLE 137 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 181
TABLE 138 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 182
TABLE 139 SPAIN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2022–2030 (USD MILLION) 182
TABLE 140 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY TYPE, 2022–2030 (USD MILLION) 183
TABLE 141 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF,
BY TYPE, 2022–2030 (USD MILLION) 183
TABLE 142 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 184
TABLE 143 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 184
TABLE 144 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 185
TABLE 145 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 185
TABLE 146 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 186
TABLE 147 REST OF EUROPE: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 186
TABLE 148 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 189
TABLE 149 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 189
TABLE 150 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 190
TABLE 151 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 190
TABLE 152 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 191
TABLE 153 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA,
BY TYPE, 2022–2030 (USD MILLION) 191
TABLE 154 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 192
TABLE 155 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 192
TABLE 156 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 193
TABLE 157 CHINA: KEY MACROECONOMIC INDICATORS 194
TABLE 158 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 194
TABLE 159 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 194
TABLE 160 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 195
TABLE 161 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS,
BY TYPE, 2022–2030 (USD MILLION) 195
TABLE 162 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 196
TABLE 163 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 196
TABLE 164 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 197
TABLE 165 CHINA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2022–2030 (USD MILLION) 197
TABLE 166 JAPAN: KEY MACROECONOMIC INDICATORS 198
TABLE 167 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 198
TABLE 168 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 198
TABLE 169 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 199
TABLE 170 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS,
BY TYPE, 2022–2030 (USD MILLION) 199
TABLE 171 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 200
TABLE 172 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 200
TABLE 173 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 201
TABLE 174 JAPAN: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2022–2030 (USD MILLION) 201
TABLE 175 INDIA: KEY MACROECONOMIC INDICATORS 202
TABLE 176 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 202
TABLE 177 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE,
2022–2030 (USD MILLION) 202
TABLE 178 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 203
TABLE 179 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS,
BY TYPE, 2022–2030 (USD MILLION) 203
TABLE 180 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 204
TABLE 181 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 204
TABLE 182 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE,
2022–2030 (USD MILLION) 205
TABLE 183 INDIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2022–2030 (USD MILLION) 205
TABLE 184 AUSTRALIA: KEY MACROECONOMIC INDICATORS 206
TABLE 185 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 206
TABLE 186 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 206
TABLE 187 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 207
TABLE 188 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 207
TABLE 189 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA,
BY TYPE, 2022–2030 (USD MILLION) 208
TABLE 190 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 208
TABLE 191 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 209
TABLE 192 AUSTRALIA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 209
TABLE 193 SOUTH KOREA: KEY MACROECONOMIC INDICATORS 210
TABLE 194 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 210
TABLE 195 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF,
BY TYPE, 2022–2030 (USD MILLION) 210
TABLE 196 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 211
TABLE 197 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 211
TABLE 198 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA,
BY TYPE, 2022–2030 (USD MILLION) 212
TABLE 199 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 212
TABLE 200 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 213
TABLE 201 SOUTH KOREA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 213
TABLE 202 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 214
TABLE 203 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 214
TABLE 204 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY PRODUCT TYPE, 2022–2030 (USD MILLION) 215
TABLE 205 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 215
TABLE 206 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 216
TABLE 207 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 216
TABLE 208 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY PATIENT TYPE, 2022–2030 (USD MILLION) 217
TABLE 209 REST OF ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY END USER, 2022–2030 (USD MILLION) 217
TABLE 210 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 218
TABLE 211 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY TYPE, 2022–2030 (USD MILLION) 218
TABLE 212 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF,
BY TYPE, 2022–2030 (USD MILLION) 219
TABLE 213 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 219
TABLE 214 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 220
TABLE 215 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA,
BY TYPE, 2022–2030 (USD MILLION) 220
TABLE 216 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 221
TABLE 217 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 221
TABLE 218 LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY END USER, 2022–2030 (USD MILLION) 222
TABLE 219 BRAZIL: KEY MACROECONOMIC INDICATORS 222
TABLE 220 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 223
TABLE 221 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 223
TABLE 222 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 223
TABLE 223 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS,
BY TYPE, 2022–2030 (USD MILLION) 224
TABLE 224 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 224
TABLE 225 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES,
BY TYPE, 2022–2030 (USD MILLION) 225
TABLE 226 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 225
TABLE 227 BRAZIL: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2022–2030 (USD MILLION) 226
TABLE 228 MEXICO: KEY MACROECONOMIC INDICATORS 227
TABLE 229 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2022–2030 (USD MILLION) 227
TABLE 230 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 227
TABLE 231 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 228
TABLE 232 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS,
BY TYPE, 2022–2030 (USD MILLION) 228
TABLE 233 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 229
TABLE 234 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 229
TABLE 235 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE, 2022–2030 (USD MILLION) 230
TABLE 236 MEXICO: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2022–2030 (USD MILLION) 230
TABLE 237 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY TYPE, 2022–2030 (USD MILLION) 231
TABLE 238 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 231
TABLE 239 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY PRODUCT TYPE, 2022–2030 (USD MILLION) 232
TABLE 240 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 232
TABLE 241 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 233
TABLE 242 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 233
TABLE 243 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY PATIENT TYPE, 2022–2030 (USD MILLION) 234
TABLE 244 REST OF LATIN AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY END USER, 2022–2030 (USD MILLION) 234
TABLE 245 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY TYPE, 2022–2030 (USD MILLION) 235
TABLE 246 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
FOR IVF, BY TYPE, 2022–2030 (USD MILLION) 236
TABLE 247 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY PRODUCT TYPE, 2022–2030 (USD MILLION) 236
TABLE 248 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 237
TABLE 249 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 237
TABLE 250 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 238
TABLE 251 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY PATIENT TYPE, 2022–2030 (USD MILLION) 238
TABLE 252 MIDDLE EAST & AFRICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY END USER, 2022–2030 (USD MILLION) 239
TABLE 253 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE, 2022–2030 (USD MILLION) 240
TABLE 254 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR IVF,
BY TYPE, 2022–2030 (USD MILLION) 241
TABLE 255 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2030 (USD MILLION) 241
TABLE 256 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2030 (USD MILLION) 242
TABLE 257 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR MEDIA, BY TYPE, 2022–2030 (USD MILLION) 242
TABLE 258 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2022–2030 (USD MILLION) 243
TABLE 259 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY PATIENT TYPE, 2022–2030 (USD MILLION) 243
TABLE 260 GCC COUNTRIES: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET,
BY END USER, 2022–2030 (USD MILLION) 244
TABLE 261 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, JANUARY 2021–MARCH 2025 246
TABLE 262 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DEGREE OF COMPETITION 248
TABLE 263 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: REGION FOOTPRINT 255
TABLE 264 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: TYPE FOOTPRINT 256
TABLE 265 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: PRODUCT TYPE FOOTPRINT 257
TABLE 266 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: PATIENT TYPE FOOTPRINT 258
TABLE 267 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: END-USER FOOTPRINT 259
TABLE 268 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DETAILED LIST
OF KEY STARTUPS/SMES 262
TABLE 269 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 263
TABLE 270 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: PRODUCT LAUNCHES,
JANUARY 2021–MARCH 2025 264
TABLE 271 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DEALS,
JANUARY 2021–MARCH 2025 264
TABLE 272 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2025 265
TABLE 273 COOPERSURGICAL INC.: COMPANY OVERVIEW 266
TABLE 274 COOPERSURGICAL INC.: PRODUCTS OFFERED 267
TABLE 275 COOPERSURGICAL INC.: DEALS, JANUARY 2021–MARCH 2025 269
TABLE 276 FUJIFILM IRVINE SCIENTIFIC: COMPANY OVERVIEW 270
TABLE 277 FUJIFILM IRVINE SCIENTIFIC: PRODUCTS OFFERED 271
TABLE 278 FUJIFILM IRVINE SCIENTIFIC: DEALS, JANUARY 2021–MARCH 2025 271
TABLE 279 FUJIFILM IRVINE SCIENTIFIC: OTHER DEVELOPMENTS,
JANUARY 2021–MARCH 2025 272
TABLE 280 VITROLIFE: COMPANY OVERVIEW 273
TABLE 281 VITROLIFE: PRODUCTS OFFERED 275
TABLE 282 VITROLIFE: DEALS, JANUARY 2021–MARCH 2025 275
TABLE 283 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 277
TABLE 284 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 278
TABLE 285 COOK MEDICAL INC.: COMPANY OVERVIEW 280
TABLE 286 COOK MEDICAL INC.: PRODUCTS OFFERED 280
TABLE 287 COOK MEDICAL INC.: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2025 281
TABLE 288 COOK MEDICAL INC.: DEALS, JANUARY 2021–MARCH 2025 282
TABLE 289 HAMILTON THORNE: COMPANY OVERVIEW 283
TABLE 290 HAMILTON THORNE: PRODUCTS OFFERED 283
TABLE 291 HAMILTON THORNE: DEALS, JANUARY 2021–MARCH 2025 284
TABLE 292 KITAZATO CORPORATION: COMPANY OVERVIEW 286
TABLE 293 KITAZATO CORPORATION: PRODUCTS OFFERED 286
TABLE 294 KITAZATO CORPORATION: DEALS, JANUARY 2021–MARCH 2025 288
TABLE 295 ESCO MICRO PTE. LTD.: COMPANY OVERVIEW 289
TABLE 296 ESCO MICRO PTE. LTD.: PRODUCTS OFFERED 289
TABLE 297 ESCO MICRO PTE. LTD.: DEALS, JANUARY 2021–MARCH 2025 290
TABLE 298 FERTIPRO NV: COMPANY OVERVIEW 291
TABLE 299 FERTIPRO NV: PRODUCTS OFFERED 291
TABLE 300 GENEA BIOMEDX: COMPANY OVERVIEW 293
TABLE 301 GENEA BIOMEDX: PRODUCTS OFFERED 293
TABLE 302 GENEA BIOMEDX: DEALS, JANUARY 2021–MARCH 2025 294
TABLE 303 LENUS PHARMA GESMBH: COMPANY OVERVIEW 295
TABLE 304 LENUS PHARMA GESMBH: PRODUCTS OFFERED 295
TABLE 305 LENUS PHARMA GESMBH: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2025 295
TABLE 306 ZITA WEST: COMPANY OVERVIEW 296
TABLE 307 ZITA WEST: PRODUCTS OFFERED 296
TABLE 308 EXELTIS USA, INC.: COMPANY OVERVIEW 298
TABLE 309 EXELTIS USA, INC.: PRODUCTS OFFERED 298
TABLE 310 VITABIOTICS LTD.: COMPANY OVERVIEW 299
TABLE 311 VITABIOTICS LTD.: PRODUCTS OFFERED 299
TABLE 312 ADVACARE PHARMA: COMPANY OVERVIEW 301
TABLE 313 ADVACARE PHARMA: PRODUCTS OFFERED 301
TABLE 314 FAIRHAVEN HEALTH: COMPANY OVERVIEW 302
TABLE 315 SHANGHAI UNICORN MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 303
TABLE 316 GYNEMED GMBH & CO. KG: COMPANY OVERVIEW 304
TABLE 317 INVITROCARE INC.: COMPANY OVERVIEW 305
TABLE 318 IVFTECH: COMPANY OVERVIEW 306
TABLE 319 LABIVF ASIA PTE LTD.: COMPANY OVERVIEW 307
TABLE 320 COAST SCIENCE: COMPANY OVERVIEW 308
TABLE 321 BIOIMAGER INC.: COMPANY OVERVIEW 309
TABLE 322 SHIVANI SCIENTIFIC: COMPANY OVERVIEW 310
TABLE 323 MINITÜB GMBH: COMPANY OVERVIEW 311
LIST OF FIGURES
FIGURE 1 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SEGMENTATION
AND REGIONAL SCOPE 30
FIGURE 2 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: RESEARCH DESIGN 34
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 38
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 39
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 40
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 41
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: COOPERSURGICAL INC., 2024 41
FIGURE 8 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION 42
FIGURE 9 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DEMAND-SIDE
MARKET SIZE ESTIMATION 43
FIGURE 10 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DYNAMICS, 2025–2030 45
FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 46
FIGURE 12 DATA TRIANGULATION 47
FIGURE 13 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TYPE,
2025 VS. 2030 (USD MILLION) 50
FIGURE 14 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT TYPE,
2025 VS. 2030 (USD MILLION) 51
FIGURE 15 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PATIENT TYPE,
2025 VS. 2030 (USD MILLION) 52
FIGURE 16 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 53
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF ASSISTED REPRODUCTIVE TECHNOLOGY MARKET 54
FIGURE 18 INCREASING INFERTILITY WORLDWIDE TO DRIVE MARKET 55
FIGURE 19 IVF SEGMENT AND CHINA DOMINATED ASIA PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET IN 2024 56
FIGURE 20 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 57
FIGURE 21 ASIA PACIFIC TO LEAD MARKET DURING FORECAST PERIOD 58
FIGURE 22 DEVELOPING MARKETS TO HAVE HIGHER CAGR DURING FORECAST PERIOD 59
FIGURE 23 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61
FIGURE 24 AVERAGE AGE OF FIRST-TIME MOTHERS IN US, 2001–2023 62
FIGURE 25 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET 71
FIGURE 26 AVERAGE SELLING PRICE TREND OF SUPPLEMENTS, BY REGION,
2022–2024 (USD) 73
FIGURE 27 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: VALUE CHAIN ANALYSIS 74
FIGURE 28 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: SUPPLY CHAIN ANALYSIS 76
FIGURE 29 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: ECOSYSTEM ANALYSIS 76
FIGURE 30 INVESTMENT AND FUNDING SCENARIO, 2019–2023 77
FIGURE 31 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 78
FIGURE 32 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 (USD MILLION) 78
FIGURE 33 PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024 81
FIGURE 34 PORTER’S FIVE FORCES ANALYSIS 93
FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO END USERS 95
FIGURE 36 KEY BUYING CRITERIA FOR TOP TWO END USERS 96
FIGURE 37 AI USE CASES 99
FIGURE 38 NORTH AMERICA: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SNAPSHOT 143
FIGURE 39 ASIA PACIFIC: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SNAPSHOT 188
FIGURE 40 REVENUE ANALYSIS OF TOP PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, 2020–2024 (USD MILLION) 247
FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, 2024 248
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS, 2025 250
FIGURE 43 EV/EBITDA OF KEY VENDORS, 2025 250
FIGURE 44 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: BRAND/PRODUCT COMPARISON 251
FIGURE 45 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 253
FIGURE 46 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: COMPANY FOOTPRINT 254
FIGURE 47 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 261
FIGURE 48 COOPERSURGICAL INC.: COMPANY SNAPSHOT (2024) 267
FIGURE 49 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT (2024) 270
FIGURE 50 VITROLIFE: COMPANY SNAPSHOT (2024) 274
FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 278
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- コンクリートシーラー市場 – 2030年までの世界予測 2025-04-21
- 自動車用ヒートシールド市場 – 2032年までの世界予測 2025-04-21
- XEVアフターマーケットの進化に関する競争力情報 – 2035年までの世界予測 2025-04-17
- アプリケーションライフサイクル管理市場 – 2029年までの世界予測 2025-04-17
- ヒンダードアミン光安定剤（HALS）市場 – 2030年までの世界予測 2025-04-17